​​​​​​​MPNEhubs 2018- by invitation only

Thursday- 15th

afternoon
arrival MPNE hub advocates

19.00

Working Dinner


Friday- 16th 

8.30- 12.30
MPNE hub meeting- for advocates involved in MPNE projects

Agenda shared closer to date.



Main conference

program 

version 12th March 2018



  • indicates parallel sessions


Friday- 16th March

13.30 - 14.00 parallel sessions


  • MPNE quickstart for newcomers

​​Facilitators

Kari Anne Fevang, MPNE and Føflekkreftföreningen, Norway

Fredrik Östman, MPNE and Melanomföreningen, Sweden


  • Meet our OM colleagues

Facilitators

Iain Galloway, Andrew Evans and Dick Plomp, MPNErare




14.00- 14.45 parallel sessions


  • Einstein Melanoma.

Es simple as possible as complicated as necessary. 

Conference opening and basic Melanoma principles explained.

Bettina Ryll, MPNE

Luc Vautmans, MPNE and Melanoompunt.be


  • An introduction to UMCURE

Emilie Vinolo, UMCURE

Iain Galloway, Andrew Evans and Dick Plomp, MPNErare 



14.45- 15.30 parallel sessions


  • ​Know your stage!

Introduction to

AJCC 8th edition- the new Melanoma staging system explained

Gilly Spurrier, MPNE

Violeta Astratinei, MPNE


Calculate your stage- the MID staging calculator

Katharina Kaminski, MID, Germany 


Bring your own pathology report to test!


  • Liquid biopsies 

What are liquid biopsies and what promise do they hold for Melanoma patients?

Thomas Schlange, CancerID

Kari Anne Fevang, Foflekkreftforeningen, Norway



15.35- 16.00
Coffee



16.00- 16.45 parallel sessions


  • Know your drugs!

Since 2011, 8 new therapies and 3 combinations have been approved in Europe for Melanoma and turned the disease around. A crash-course or re-fresher on how we get our drugs, what they are, how they work and for whom.


Drug approval in a nutshell

Violeta Astratinei, MPNE


Overview of Melanoma therapies approved since 2011

Gilly Spurrier, MPNE


  • It's ok, nobody else here knows what a p-value is either

Darren Dahly, UCC, Ireland

Kay Curtin, Melanoma Support Ireland, Ireland


  • Pharmacogenomics

Tomas Kirchhoff, Perlmutter Cancer Centre, New York

Bettina Ryll, MPNE


  • Genetic and cellular heterogeneity in Uveal Melanoma

Pieter van der Velden, LUMC, Netherlands

Martine Jager, LUMC, Netherlands

Andrew Evans, MPNErare



16.50- 17.30parallel sessions


  • Making hazard ratios less hazardous.

    Those pesky little details- spikey Kaplan Meier curves? Why not to trust the curve tail?
    Darren Dahly, UCC, Ireland

   Fredrik Östman, Melanomföreningen, Sweden


  • Coping with Melanoma

    A Melanoma diagnosis places a heavy burden on both patient and family. What are effective coping strategies? What can we advise newly diagnosed patients?

    Kay Curtin, Melanoma Support Ireland, Ireland

   Luc Vautmans, Melanoompunt.BE, Belgium


  • Life is more than surviving- how to deal with side effects

    Grateful for being alive but suffering from side effects of new therapies- what can we do to ensure that side effects are detected earlier and treated effectively?

    Gilly Spurrier, MPNE

   Susannah Archer, Melanomamates, UK


  • To biopsy or not?

    Genetic characterisation is of great prognostic value in OM. However, patients have concerns that choroidal biopsies increase the risk of metastasis. Currently, only weak evidence is available- what to do?

    Marina Marinkovic, LUMC, NL
    Dick Plomp, MPNErare



17.45- 18.30

Fireside chat- the future in melanoma

Tomas Kirchhoff, Perlmutter Cancer Centre, New York

Ioannis Karydis, Southampton

Bettina Ryll, MPNE

 

19.00

World Cafe reception- at the Edge.

Anne Wispler, Hans Boetl and Martina Kiehl, Hautkrebsnetzwerk Germany


20.00

Welcome Dinner



Saturday- 17TH MARCH


8.45- 9.00

Welcome to the conference and introduction to the day

Bettina Ryll, MPNE


Knowledge protects. Read Scientific Literature in the Original.

Saturday morning will be dedicated to provide participants with the necessary tools and techniques to read Melanoma Scientific Studies as original publication. 

We will provide publications, a thorough introduction, explanations of concepts and a glossary of tricky terms. 

And as the ESMO Magnitude of Clinical Benefit Scale provides a useful tool to extract THE bits of information out of a paper that really matter- we shall do that, too. Hands-on experience on publications that matter in Melanoma promised! 



9.00- 10.30 

Session 1- Science for Melanoma patient advocates

​1.1 Why Science matters for Melanoma patients 

Bettina Ryll, MPNE

1.2 How to access Scientific Literature and MPNE resources 

Gilliosa Spurrier, MPNE

1.3 The ESMO Magnitude of Clinical Benefit Scale, MCBS- an introduction

Elisabeth de Vries, Netherlands

1.4 How to use the MCBS material

Nicola Latino, ESMO


10.30- 11.00

GROUP PHOTO

Coffee 


11.00- 12.30 

Session 2- practical exercises: how to read a scientific Melanoma paper

we will work in groups, articles and material will be provided

 

12.30- 13.30 

Lunch


13.30- 15.00 parallel sessions

Session 3


  • The new frontier in (cutaneous) Melanoma

Piotr Rutkowski, Warsaw

Bettina Ryll, MPNE


  1. Treatment options for Melanoma Stage 3
  2. Overcoming resistance
  3. ​When to stop treatment



  • Ocular Melanoma updates

13.30- 14.45 Update on Uveal Melanoma therapies with special focus on liver-directed therapies

Ioannis Karydis, Southampton, UK

Jo Gumbs, OcuMel, UK


14.45- 15.30 The genetics of Uveal Melanoma

Tomas Kirchhoff, NY

Andrew Evans, MPNErare



15.00- 15.30

Session 4- Quality of Life and that tricky business of conducting good qualitative research
Jens Kongsø, Copenhagen

Gilly Spurrier, MPNE


​15.30- 16.00

Coffee


​16.00- 17.00 parallel sessions

Session 5


  • The Molecular Biology of Melanoma

​Chris Marine, VIB, Leuven, Belgium 

Bettina Ryll, MPNE

Why do some Melanomas progress and others don't?

And why are there some Melanomas that never respond or stop responding to therapy?

Understand what Science knows so far- and what the next big questions are.


With the long-requested introduction to some Molecular Biology techniques :-)


  • Introduction to Dermoscopy

Zrinjka Pastar, Udruga Melanom, Croatia

Anca Andronic, Melanom Romania, Romania


  • Who in Ocular Melanoma responds to anti-PD1s? 

​Manuel Rodrigues, IGR, France

Iain Galloway, MPNErare




17.15- 18.15 parallel sessions

Focus sessions


  • Stage 3- Improving your chances to survive
  • Pragmatic Clinical Trials
  • Improving the early detection of Melanoma with special focus on groups at risk
  • Running qualitative research on your patient forum


 

18.30- 20.00

Reception and Poster competition 

Ideas worth sharing- the Melanoma Advocacy Project.

Kari Anne Fervang, Føflekkkreftforeningen, Norway


Advocacy speed dating

Meet your advocacy colleagues in a fun way to get a chance to pick their brains! We will be running several smaller sessions during the Reception and Poster exhibition, please sign up during the day!

​Tom van der Velde, Melanoompunt.be


20.00 

Conference Dinner

Marivaux Hotel, restaurant


Sunday- 19th MARCH
Advocacy Day- for patient advocates only

please make sure you check out in the morning


8.45- 9.30

Session 4 

4.1 MPNE - our network, our principles and evidence-based advocacy

Bettina Ryll, MPNE

4.2 MPNE Kahoot!

Test your Melanoma knowledge!



9.30- 10.30

Advocacy Workshops- parallel sessions


  • How to organise a patient conference
  • What advocates can learn from start-ups: Best of Krusenberg 2017
  • A margarita with your oncologist- let's talk about communication
  • How to run a patient forum
  • Smarter trials: adaptive (Bayesian) designs



10.30- 11.00

Coffee 


11.00- 12.30

The best of the network in 2017


Advocacy in Action

moderator- Gilly Spurrier, MPNE

10' Building capacity in your network: IPOSSI- the Irish Experience

Kay Curtin, Melanoma Support Ireland, Ireland

10' Organising the psycho-social support you need
Andreea Strambu Dima, Melanom Romania, Romania

10' Improving processes to improve lives. A research project by Melanoompunt.be.

Luc Chalmet, Melanoompunt.be, Belgium

10' questions and discussion


Data, the new gold. But whose gold is it? Patient Registries

moderator- Bettina Ryll, MPNE

10' The UK experience

Diane Cannon, Melanoma UK

10' What are blockchains? And why should we bother?

Andrew Evans, MPNE

10' Diskussion 'the patient registries we need'


10' Breaking that glass ceiling- getting ahead in advocacy

Iain Galloway, MPNE


12.30- 12.45

Closing Session

Conference Summary and Conclusion


13.00

Lunch and departure




​We are looking forward to seeing you!

the program


​What is the AJCC?

The American Joint Committee on Cancer (AJCC) established the way cancer is communicated. Clinicians and the surveillance community count on the AJCC for the most comprehensive anatomic staging data available, the Cancer Staging Manual and Cancer Staging Atlas.
These AJCC publications are recognized as the authoritative guides for cancer staging information and are used by tens of thousands of medical professionals everyday.

Read more 

poster competition

mPNE2018


Quickstart for firstcomers 

an introduction to who we are and how our conferences work!


Ideas worth

sharing in  

melanoma


Program in a reader and for download


Surviving Melanoma in Europe.  

Access to prevention, early detection and effective treatment for all.

Melanoma Patient Network Europe

MPNE 2018


Annual conference


16th- 18th March 2018

Marivaux Hotel, Brussels, Belgium​​